Concerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred survey
- PMID: 32616604
- DOI: 10.1136/annrheumdis-2020-217967
Concerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred survey
Keywords: epidemiology; hydroxychloroquine; lupus erythematosus, systemic.
Conflict of interest statement
Competing interests: GC received scientific grants, travel support, or honoraria from Glaxo Smith Kline and UCB Pharma, unrelated to this manuscript. PK received personal fees, travel support, or honoraria from Abbvie, Bristol-Myers Squibb, Chugai, Glaxo Smith Kline, Novartis, and Pfizer, all unrelated to this manuscript.
Comment in
-
Response to: 'Concerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred survey' by Plüß et al.Ann Rheum Dis. 2021 Apr;80(4):e53. doi: 10.1136/annrheumdis-2020-218069. Epub 2020 Jul 2. Ann Rheum Dis. 2021. PMID: 32616603 No abstract available.
Comment on
-
Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine.Ann Rheum Dis. 2020 Jun;79(6):837-839. doi: 10.1136/annrheumdis-2020-217566. Epub 2020 Apr 24. Ann Rheum Dis. 2020. PMID: 32332072 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical